Synthesis of phosphomannan antigens found in the Candida albicans cell wall Ingenuity Centre for





Department of Chemistry, University of Alberta, Edmonton, Alberta, Canada, T6G 2G2

Introduction

rbohydrate Science

Alberta

Candida albicans is the most common etiologic agent in candidiasis a serious infection that affects immunocompromised patients or those undergoing long-term antibiotic treatment. The cell wall phosphomannan of C. albicans (Figure 1) is a promising target for the induction of immunity by development of a conjugate vaccine. It contains a unique antigen, a β1,2-mannan, that affords active protection to mice following immunization and subsequent challenge with live organisms.

We are investigating the use of short oligosaccharides conjugated to suitable carriers [1,2] as viable conjugate vaccines since oligosaccharides of this size are sufficiently well organized to induce mannan specific antibodies. The ordered solution three-dimensional structure determined for oligo β 1,2-mannan shows that the oligosaccharide approximates a helix with three hexose residues per turn (Figure 2). This helical conformation has been observed in solution by NOE NMR experiments and the trisaccharide segment corresponds with the most potent trisaccharide inhibitor [3].



Figure 1 Candida albicans phosphomannan (side chain lengths vary)

Figure 2 Global minimum energy structure of β1,2-mannan

Synthesis

The phosphodiester bridge between the β-mannan and the α-mannan could be an essential element of a vaccine construct. Here we report our efforts towards the chemical synthesis of di- and trisaccharide epitopes attached via a phosphodiester linkage that mimics a portion of the phosphomannan.



Conclusion and perspectives

We have demonstrated the efficiency of the phosphoramidite coupling for obtaining phosphodiester linkages under mild reaction conditions at the reducing end of a β 1,2-mannan motif.

The synthesis remains to be optimized. In addition, coupling of trisaccharide hemiacetal 3 to phosphoramidites 4 and 5 will be performed.

Following deprotection of the carbamate, the free amines will be used to couple the synthesized antigens to a protein carrier to generate conjugate vaccines.

Acknowledgments

Financial support for this work was provided by research grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Alberta Ingenuity Centre for Carbohydrate Science.

References

- 1. M. Nitz, B. W. Purse and D. R. Bundle, Org. Lett., 2 (2000) 2939-2942.
- M. Nitz and D. R. Bundle, J. Org. Chem., 66 (2001), 8411-8423. 2.
- 3. M. Nitz, C.-C. Ling, A. Otter, J. E. Cutler and D. R. Bundle, J. Biol. Chem., 277 (2002), 3440-3446
- 4. F. W. Lichtenthaler, T. Schneider-Adams and S. Immel, J. Org. Chem., 59 (1994). 6735-6738.